STAT+: AstraZeneca invests $2 billion in Summit Therapeutics
Stat News • 9/29/2026
Summary
AstraZeneca is investing $2 billion in Summit Therapeutics. The collaboration will involve testing Summit's PD-1/VEGF bispecific ivonescimab alongside AstraZeneca’s antibody-drug conjugates.
Advertisement
Lindy Score Breakdown (V4.2)
2h
Age
1
Sources
from cluster
1
Hours Since Seen
Final Score12/100
CategoryAntiLindy
StatusActive
Recency Multiplier99% (0.5^1/48)
Hero EligibleYes
Score BreakdownRisk 70
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: Breaking news - too recent to assess longevity
Stories gain Lindy status through source reputation, network consensus, and time survival.
Breaking Similar stories
STAT+: Once described as obesity medicines for ‘patients,’ GLP-1s are increasingly lifestyle drugs for ‘customers’
Stat News • 1 day ago
STAT+: AbbVie wins FDA nod for Parkinson’s pill
Stat News • 1 day ago
STAT+: It really is bleak out there, and list prices matter
Stat News • 1 day ago
STAT+: The last ‘breakthrough’ devices to get special treatment from Medicare
Stat News • Today
STAT+: UniQure’s gene therapy continues to slow Huntington’s progression after four years
Stat News • Today
STAT+: Merck discontinues a crucial antibiotic despite concerns over superbug resistance
Stat News • Today
STAT+: Anthropic joins ARPA-H clinical AI moonshot, will hold closed-door health care event
Stat News • Today
STAT+: Drug pricing, Medicaid, and research funding: The key policy issues at stake in the midterms
Stat News • Today
STAT+: Pharmalittle: We’re reading about Novo licensing a Chinese obesity pill, Merck pulling an antibiotic, and more
Stat News • Today
STAT+: Pharmalittle: We’re reading about GLP-1s becoming lifestyle drugs, a setback for Merck and Daiichi, and more
Stat News • 1 day ago
